[ad_1] STOCKHOLM, Nov. 6, 2024 /PRNewswire/ — BioArctic AB (publ) (NASDAQ STOCKHOLM: BIOA B) will publish the company’s third quarter report for July – September 2024 on Thursday, November 14, 2024, at 08:00 a.m. CET. […]
Tag: BioArctic
Eisai completes rolling BLA submission for subcutaneous maintenance dosing of Leqembi® (lecanemab-irmb) in the US
[ad_1] STOCKHOLM, Oct. 31, 2024 /PRNewswire/ — BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Eisai has completed the rolling submission of a Biologics License Application (BLA) to the U.S. Food […]
Lecanemab data presented at CTAD on early initiation and long-term treatment suggest increased patient benefit with maintained safety profile
[ad_1] STOCKHOLM, Oct. 31, 2024 /PRNewswire/ — BioArctic AB’s (publ) (NASDAQ Stockholm: BIOA B) partner Eisai has presented the latest findings for lecanemab (Leqembi®) at the Clinical Trials on Alzheimer’s Disease, CTAD, congress, held in […]
Professor Lars Lannfelt, awarded the CTAD Lifetime Achievement Award in recognition for his pioneering work in Alzheimer’s Disease
[ad_1] STOCKHOLM, Oct. 30, 2024 /PRNewswire/ — BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that BioArctic’s co-founder, Professor Lars Lannfelt, was awarded the Lifetime Achievement Award in Alzheimer’s Disease Therapeutic Research at the […]
Lifetime Achievement Award, lecanemab and biomarkers in focus at CTAD
[ad_1] STOCKHOLM, Oct. 24, 2024 /PRNewswire/ — BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) founder Lars Lannfelt will be presented with the Lifetime Achievement Award in Alzheimer’s Disease Therapeutic Research at the Clinical Trials for […]
